Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating lorundrostat for the treatment of uncontrolled …
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat Read More
SPRING HOUSE, PA — Johnson & Johnson has unveiled new data from Phase 3 trials for icotrokinra (JNJ-2113), an investigational oral peptide targeting the IL-23 receptor, showing significant promise for treating …
Johnson & Johnson Advances Psoriasis Treatment with Promising Icotrokinra Results Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has scheduled a conference call and webinar on Monday, March 10, 2025, at 8:00 a.m. ET to present topline results from its …
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat Read More
JENKINTOWN, PA — SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate aimed at treating mild-to-moderate psoriasis. The study demonstrated both …
SFA Therapeutics Reports Promising Phase 1b Results for Oral Psoriasis Treatment Read More
BERWYN, PA — Mural Health Technologies, Inc. has announced a strategic partnership with ICON to implement its Mural Link participant management and payments platform in clinical trials. The collaboration is designed …
Mural Health Partners with ICON to Enhance Clinical Trial Participation Read More
BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has commended Nanomerics for the successful completion of a human study utilizing its proprietary Molecular Envelope Technology (MET). The Phase I SUNLIGHT trial …
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a significant milestone with the U.S. Food and Drug Administration (FDA), gaining alignment to advance its Phase 2/3 pivotal confirmatory trial of OCU410ST, …
FDA Greenlights Ocugen’s Breakthrough Gene Therapy Trial, Offering New Hope for Stargardt Disease Patients Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, demonstrating the potential of Rezdiffra (resmetirom) to significantly reduce liver stiffness in …
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy Read More
DOYLESTOWN, PA — Sterotherapeutics has initiated a Phase 2 clinical trial for ST-002, an innovative drug candidate aimed at treating Cushing’s Syndrome, a rare and severe endocrine disorder. The launch represents …
Sterotherapeutics Launches Phase 2 Trial for Cushing’s Syndrome Drug Read More SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately …
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis Patients Read More